Overview of Hystolan

Quick Facts: Hystolan

Property	Description
Active ingredient	Isoxsuprine Hydrochloride
Form	Oral Tablet (most common), Injection Solution
Pharmacological class	Peripheral Vasodilator, beta-adrenergic agonist
General purpose	Improving peripheral blood flow, reducing muscle tension
Origin	Synthetic small molecule

What Type of Medicine Is Hystolan (Isoxsuprine)?

Hystolan is a synthetic, single-ingredient medication with the active compound Isoxsuprine Hydrochloride. It is clinically recognized and classified primarily as a Peripheral Vasodilator and beta-adrenergic agonist, utilized therapeutically for its ability to affect smooth muscle.

This pharmacological identity defines Hystolan as a drug that acts directly on physiological systems. Isoxsuprine is chemically identified as a 2-amino-1-phenylethanol derivative and is also classified as a Tocolytic Agent due to its specific effect on the uterus. Its synthetic nature ensures a reliable pharmacological profile, a key differentiating factor from complex natural remedies. The drug acts on the peripheral circulatory system, supporting its role in promoting better circulation to areas of the body.

Composition, Origin, and Common Forms

Hystolan is most commonly encountered in the form of an Oral Tablet, making it suitable for convenient daily intake, although it is available for other routes of administration. The core ingredient, Isoxsuprine Hydrochloride, is a chemically manufactured, non-biological substance with a consistent composition.

The composition involves the active ingredient combined with pharmaceutically inert solid excipients necessary for forming the tablet structure. While the oral tablet is the primary form, Isoxsuprine is also prepared as a sterile Aqueous Solution when the intramuscular or intravenous route of administration is required. This consistent, manufactured origin provides predictable stability and pharmaceutical quality, necessary for its function as a prescription-only agent.

What Is the General Purpose of This Drug Class?

The general purpose of Hystolan is to address issues related to constricted circulation and muscle tension through a targeted action on smooth muscle tissue. By engaging specific receptors, the drug’s vasodilatory function causes the walls of blood vessels to widen, resulting in vasodilation and a subsequent increase in blood flow to tissues.

This fundamental physiological action is the basis for its therapeutic class, benefiting situations where adequate peripheral blood flow is compromised. Furthermore, the capacity of Isoxsuprine to relax the smooth muscle of the uterus provides a general function focused on reducing unwanted muscular activity in that specific organ system.

What side effects are possible with Hystolan?

Possible Side Effects and Safety Information

Hystolan (isoxsuprine) is a peripheral vasodilator, and its safety profile includes specific cautions and documented adverse reactions common to this class of medication.

Adverse Reactions

The most common adverse effects associated with isoxsuprine often relate to its effect on the circulatory system, including dizziness and weakness. Other reported side effects may include:

Cardiovascular: Palpitations (irregular or bothersome heartbeats), chest pain.
Gastrointestinal: Nausea, vomiting.
Dermatologic/Allergic: Rash, skin flushing, or symptoms of a more serious allergic reaction such as difficulty breathing or swelling of the face, tongue, or throat.

While a formal frequency classification (e.g., very common, rare) based on global regulatory standards is not consistently documented across all sources for Hystolan, these are the clinically significant effects observed with its active compound.

Safety Considerations and Restrictions

Certain conditions or concurrent activities require particular caution or contraindicate the use of Hystolan:

Pregnancy: Hystolan is not recommended for use during pregnancy as safety has not been established. It is also generally contraindicated immediately after childbirth (postpartum) or in individuals with active bleeding disorders.
Operating Machinery: Due to the potential for dizziness and weakness, caution is advised when driving, operating heavy machinery, or performing other hazardous activities.
Alcohol Consumption: The safety of Hystolan when used with alcohol has not been established, and consultation is necessary.

Individuals should monitor for any adverse effects, particularly persistent dizziness, irregular heartbeats, or signs of an allergic reaction. Any concerns should be addressed with a healthcare professional.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based exclusively on the official overdose descriptions found in government regulatory documents and prescribing information for Hystolan (Isoxsuprine Hydrochloride).

Documented Overdose Manifestations

Overdose is primarily characterized by effects related to the drug's action on the circulatory system. Symptoms and signs formally documented in regulatory sources include:

Cardiovascular Effects: Hypotension (low blood pressure) and Tachycardia (abnormally fast heart rate).
Systemic Symptoms: Weakness, lightheadedness, nausea, and vomiting.

A severe outcome that may occur is fainting (syncope), which is associated with profound circulatory instability.

Regulator-Required Emergency Actions

Immediate medical attention is required for any suspected overdose due to the potential for severe cardiovascular compromise. Official guidance mandates two primary actions:

Seek Emergency Medical Attention: It is officially required to seek emergency medical attention or contact a poison control center for guidance.
Call Emergency Services: Urgent action by calling emergency services (such as 911) is required if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management and Treatment

No specific single antidote is listed in the official documents. Management is procedural and supportive:

For oral overdose, gastric lavage is a formally described management procedure.
A medical professional may administer a nonselective beta-blocker to manage the beta-adrenergic effects if deemed necessary.

Therapeutic Uses of Hystolan

What Hystolan Treats: Main Uses and Benefits

Hystolan is used in the symptomatic management of physical discomfort associated with poor blood flow, relevant across domains including the extremities and the brain. It is applied where additional symptomatic support is needed for chronic circulatory issues, including conditions like arteriosclerosis, Buerger's disease, and Raynaud's phenomenon. It helps address symptom clusters that may become intense or disruptive, such as coldness, numbness, tingling, and cramping pain in the limbs. The medication is also relevant in clinical settings that involve acute or unstable symptom patterns associated with the obstetric domain. It is commonly used for conditions presenting with acute episodes, such as excessive or premature uterine contractions and severe dysmenorrhea. This provides support that helps ease the overall symptom burden and may assist with maintaining functional stability when symptoms interfere with routine activities.

“This medication is commonly used when short-term symptomatic assistance is needed for both circulatory and uterine tension issues.”

Quick Fact: Relief for Vascular and Uterine Symptoms

Therapeutic Focus	Primary Symptom Relief
Vascular Support	Easing coldness, numbness, and ischemic pain in the limbs
Uterine Support	Moderating excessive or premature contractions

Regulatory References

NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Hystolan (Isoxsuprine) — Official Regulatory Information

The eligibility profile for Hystolan is defined by official regulatory documents, establishing specific criteria for use, restrictions, and absolute contraindications. Use is primarily documented for adult patients.

Absolute Prohibitions and Contraindications

Classification	Population or Condition
Contraindicated	Patients immediately postpartum (following childbirth)
Contraindicated	Patients with active Arterial Bleeding
Not Recommended	Use for Premature Labor (neither approved nor recommended)

Age and Condition Restrictions

Population Group	Eligibility Status
Geriatrics (Age 65+)	Use is generally avoided (classified as a Potentially Inappropriate Medication)
Pediatrics	Safety and effectiveness have not been established (use not recommended)
Syncope History	Use should be avoided
Severe Cardiovascular Disease	Use with caution

Pregnancy and Lactation

Hystolan is classified as FDA Pregnancy Category C. It should be used only when the potential benefit justifies the potential risk to the fetus. It is not known if the medication passes into breast milk, requiring a risk-benefit assessment for use during lactation.

In the United States, the distribution of this product is prohibited as the FDA has classified it as an unapproved new drug.

What should I know about interactions with other medicines?

The interaction profile for Hystolan (Isoxsuprine Hydrochloride) is governed primarily by its vasodilatory activity, leading to a documented risk of pharmacodynamic reinforcement.

Interaction Scope

Medicinal Product Categories	Officially Documented Interaction	Outcome
Anti-hypertensive drugs	Pharmacodynamic Reinforcement	Risk of Severe Hypotension
Other Vasodilators	Pharmacodynamic Reinforcement	Risk of Severe Hypotension

Officially Documented Interaction Statements:

Co-administration with other vasodilators is formally associated with the risk of severe hypotension due to additive blood pressure-lowering effects.
Similarly, co-administration with anti-hypertensive drugs carries the same potential risk of severe hypotension.
The regulatory prescribing information does not formally specify interactions mediated by major metabolic enzymes (e.g., CYP) or drug transporters (e.g., P-gp).
Timing-based interaction rules are not documented as mandatory for risk mitigation.
No specific food interactions are reported in official documentation, and the interaction status with alcohol is formally listed as unknown.

Interaction Classifications (High-Level)

Contraindicated Combinations: None are explicitly listed as drug-drug combinations for oral use.
Interaction Severity Classification: Risk of Severe Hypotension (as defined by the FDA Prescribing Information).

Connection to the overall interaction profile: The official interaction structure is defined by the sole documented pharmacodynamic interaction involving the potential for additive effects with other vascular-acting medications. Regulatory information establishes a specific risk outcome (severe hypotension) for these combinations, but it is silent on pharmacokinetic (CYP/transporter), food, or mandatory timing-based interaction constraints.

Mechanism of Action

beta2-Adrenergic Receptor Agonism and Smooth Muscle Relaxation

Isoxsuprine's primary function is as an agonist at the beta2-adrenergic receptors (beta2-ARs) located on the smooth muscle of peripheral blood vessels and the uterus. This binding mimics the action of natural signaling molecules, initiating an internal cascade that is applied to modulate the physical tone of these muscle tissues.

️ Intracellular cAMP Cascade and Vascular Modulation

The receptor engagement triggers the Cyclic AMP (cAMP) signaling pathway, leading to a rapid reduction in free intracellular Calcium ( Ca^2+). This molecular cascade modifies early steps that shape systemic physiological outcomes, causing the smooth muscle to relax. This physiological change results directly in vasodilation and a subsequent adjustment of peripheral perfusion and a reduction in peripheral vascular resistance.

️ Mechanistic Constraints and Feedback Regulation

The vasodilatory action is subject to the body’s own baroreceptor reflex, a compensatory regulatory feedback mechanism that physiologically counteracts the change in vascular resistance. The identical intracellular signaling cascade occurring in the uterus produces a specific modulation of its contractility. Furthermore, the capacity for the mechanism to produce relaxation is functionally constrained in structurally diseased or rigid vessels.

Dosage and Administration Information

How Hystolan is Used: Official Administration Guidelines

The following description outlines standard parameters for the administration and dosing of Hystolan (Isoxsuprine Hydrochloride).

Official Routes and Dosage

Hystolan is most commonly prescribed in the form of an Oral Tablet for administration by mouth. Although the active ingredient, Isoxsuprine, is also available for intravenous (IV) or intramuscular (IM) injection, the oral tablet is the primary form used for ongoing management.

Administration Detail	Official Instruction
Route of Administration	Primarily Oral (by mouth).
Standard Adult Dose	10 mg to 20 mg per dose (Oral Tablet).
Dosing Frequency	Three or four times daily, taken at regular intervals.

Practical Administration Instructions

The standard protocol involves specific steps for proper intake and schedule management:

Method of Intake: The oral tablet is typically swallowed whole with a full glass of water.
Missed Dose Rule: If a dose is missed and the time for the next dose is approaching, the standard procedure is to skip the missed dose and resume the regular schedule. A double dose should not be taken to compensate.

Population-Specific Guidance

Clinical practice includes specific considerations for prescribing in certain populations. For Older Adults, caution is applied in dose selection, with a general approach to initiate therapy at the lower end of the standard dosing range.

Recent Clinical Evidence

Hystolan: Recent Clinical Evidence

The following summary describes the types of research that have explored the use of Hystolan (Isoxsuprine) for its studied indications, focusing only on the structure of the evidence and the acknowledged limitations and research gaps.

Evidence for Use in Managing Peripheral Circulation Issues

Clinical investigation in this area primarily involved older, small-scale controlled trials exploring the use of Hystolan in adult patients with conditions like intermittent claudication. Researchers examined objective physiological measures of regional blood flow and functional outcomes like walking distance. Findings were mixed; Hystolan was evaluated as a peripheral vasodilator, but some controlled trials reported that objective measurements of blood flow or walking distance were not consistently measured to change during the study period. Because this research is older and its findings varied, the evidence quality supporting this indication is designated as low in some regulatory assessments.

Evidence for Use in Managing Uterine Contractions

Research has explored Hystolan for use in managing excessive uterine contractions in pregnant women, a scenario relevant to trials assessing short-term symptom patterns. The evidence includes systematic reviews and randomized controlled trials that compared Hystolan to placebo or other specific comparison agents. Studies examined outcomes related to the ability to achieve uterine quiescence and the length of the pregnancy latency period. While acute intervention studies examined the duration of the latency period, findings for the oral form when used as long-term maintenance therapy were observed to be mixed and heterogeneous across different studies.

Long-Term Follow-up and Research Gaps

Studies focused primarily on short-term responses, meaning that follow-up durations were limited, and long-term effects are not fully established. For both indications, there is limited information on the persistence of functional patterns that were measured. Furthermore, regulatory reviews in some regions have noted that the evidence base has been characterized by a lack of substantial, adequate, and well-controlled studies. Data for specific subgroups, such as older adults with multiple pre-existing health conditions or pediatric populations, also remain insufficient or uncertain for both indications.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Hystolan (FAQ)

Q: Is it common to feel tired when starting Hystolan?

Official safety information reports weakness as a known adverse reaction associated with this medicine. Weakness is a reported adverse reaction in official safety information. Feeling tired is not universally listed, but is a common subject of user inquiry.

Q: What types of food interactions are listed for Hystolan?

Official regulatory documentation does not list specific food interactions, and some authoritative sources indicate the medicine can be administered with or without food. This means there is no formal warning about food affecting its absorption or activity.

Q: Can Hystolan be taken with my daily vitamin or mineral supplements?

Official drug interaction information focuses primarily on warnings related to other vasodilators and anti-hypertensive drugs. No specific warnings or documented risks regarding common vitamin or mineral supplements are formally listed in the regulatory prescribing information.

Q: Can men use Hystolan?

Yes, official indications for this medicine, such as those related to improving peripheral vascular disease, are applicable to adult patients generally. Use is not restricted by gender, though one of the drug's mechanisms of action is specific to the uterus.

Q: What are the rules about using Hystolan during pregnancy?

This medicine is classified as FDA Pregnancy Category C. Official information indicates it should be considered for use only when a healthcare professional determines the potential benefits outweigh the potential risks. It is formally contraindicated for use immediately after childbirth (postpartum).

Q: Does Hystolan affect birth control pills?

Official drug interaction information primarily warns about other vasodilators and anti-hypertensive drugs. No specific warnings or documented pharmacokinetic interactions regarding common medications like oral birth control pills are formally listed in the regulatory prescribing information.

Q: Are there generic versions of Hystolan available?

The active ingredient in this medicine is Isoxsuprine Hydrochloride. This generic name is often used on product labels, confirming that the compound is available in generic versions.

Q: What happens if I miss a dose of Hystolan?

Official regulatory instructions from sources like MedlinePlus state that if a dose is missed and it is near the time for the next dose, the missed dose should be skipped entirely. Taking a double dose to make up for the missed one is advised against.

Q: Is Hystolan taken with food or on an empty stomach?

Regulatory guidance suggests that the medicine can be taken either with or without food. Some authoritative sources indicate that taking the tablet with meals, milk, or antacids may be an option if stomach upset is experienced.

Q: What happens when you stop taking Hystolan?

Official guidance advises against making the decision to stop the medication on one's own, even if the person feels that it is not working as expected. The decision to discontinue use or change the dose is reserved for the prescribing professional.

Q: Is Hystolan a type of hormone treatment?

No, Hystolan is classified as a Peripheral Vasodilator and a beta-adrenergic agonist, which is a drug class that acts on the smooth muscle of blood vessels and the uterus. It is not considered a type of hormone treatment.

Q: How long does it usually take to notice an effect from Hystolan?

Based on pharmacokinetic data reported in official documents, the medicine typically reaches its highest concentration in the bloodstream about one hour after it is taken by mouth.

Q: Does Hystolan cure the condition, or just manage symptoms?

The official regulatory indications for this medicine state that it is for the relief of symptoms associated with certain conditions. This means it is authorized for the management of symptoms rather than for a permanent curative effect.

Q: Is Hystolan suitable for people over 65?

Official prescribing information recommends that caution be used when selecting a dose for older adults (age 65 and above). It is formally instructed that therapy initiation should be considered at the lower end of the standard dosing range for this population.

Q: Is Hystolan a long-term or short-term medicine?

Clinical evidence summaries note that research studies generally focused on short-term responses, meaning the drug's full effects over extended periods are not completely established. The specific duration of use is determined by the healthcare professional treating the condition.

Q: Is Hystolan addictive?

Official drug information from regulatory-sourced databases, such as MedlinePlus, reports that no habit-forming tendency has been documented for this medication.

Q: What if I feel worse after starting Hystolan?

Regulatory safety guidance indicates that any unexpected side effects, or a feeling that a condition is worsening, should be discussed with a healthcare professional as soon as possible for evaluation.

Q: Is it normal to have mild headaches with Hystolan?

Although not universally listed in all primary prescribing documents, headache is reported in some authoritative medical sources as a possible side effect of this medication.

Q: What is the shelf life of Hystolan tablets?

The medicine has a limited shelf life, and the precise expiration date is printed directly on the product's container label. Regulatory guidance advises against keeping or using medicine that has passed its stated expiration date.

Q: Can I take Hystolan if I have a liver condition?

Official contraindications do not specifically prohibit use in those with liver disease. However, caution is warranted in patients with liver or kidney issues, as some authoritative resources indicate these patients may be more sensitive to the drug's effects.

Q: How quickly does Hystolan leave the body?

Pharmacokinetic information reports that the plasma half-life of the medication is approximately 1.5 hours. The half-life is a scientific measurement that indicates the time it takes for half of the drug to be eliminated from the bloodstream.

Q: Why does the packaging say Hystolan should not be used by children?

Official regulatory labeling explicitly states that the safety and effectiveness of the medicine have not been established in pediatric patients. This lack of established data is the regulatory basis for the restriction on its use in children.

Q: Are there studies about Hystolan's long-term effects?

Official regulatory reviews have noted that existing studies generally focused on short-term outcomes. Consequently, information on the drug's functional patterns and full range of effects over long-term follow-up is not fully established.

Q: Do I need to change my diet while taking Hystolan?

Official regulatory information does not document mandatory changes to a person's diet while taking this medicine. The main warnings pertain to potential interactions with other medications that affect blood pressure.

Q: Is Hystolan considered a controlled substance?

Based on the federal drug scheduling in the United States, the active ingredient in Hystolan is not classified as a controlled substance and is not subject to the special storage and prescribing rules of those medications.

Q: What should I do if I accidentally take too much Hystolan?

Signs of taking too much medicine can include a severe drop in blood pressure (hypotension) or a fast heartbeat. Regulatory-based safety advice indicates that professional medical attention should be sought immediately in an instance of suspected overdose.

Q: Are there any known allergic reactions to Hystolan?

Yes, regulatory documents report that rash and, on rare occasion, severe rash have been associated with this medicine. Symptoms of a severe allergic reaction, such as difficulty breathing or swelling, also warrant immediate professional attention.

Q: Can I crush or chew the Hystolan tablet?

Official administration instructions state that the oral tablet should be swallowed whole with a full glass of water. There are no instructions in official sources that permit crushing, chewing, or breaking the tablet.

Q: Is there a maximum time someone can stay on Hystolan?

Regulatory documents do not define a specific maximum duration of use for all patients. The period for which the medicine is prescribed is a clinical decision determined by the healthcare professional managing the underlying condition.

How should Hystolan be stored and disposed of?

The official regulatory guidelines for Hystolan (Isoxsuprine Hydrochloride) specify mandatory conditions for storage and disposal to preserve the drug's stability and ensure safety.

Storage Conditions

Labeled Storage Temperature:	Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F) [1].
Handling Requirements:	The medicine must be kept in its container tightly closed and should not be frozen [2].
Protection:	Protect from excessive humidity and keep out of the sight and reach of children [2, 3].

Official Disposal Instructions

Unused or expired Hystolan must be disposed of according to local pharmaceutical waste disposal regulations [3]. Regulatory information advises against flushing the medication down the toilet or pouring it into a drain unless explicitly instructed to do so. The recommended method is to use a community drug take-back program where available [3].

[1] FDA. DailyMed. [2] EMA. SmPC. [3] NIH. MedlinePlus.

Hystolan